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In recent years various potential mechanisms possibly involved in
the development of drug resistance in melanoma cells were
discussed. The exact mechanisms conferring the high intrinsic
drug resistance of melanoma are currently unknown. In order to
elucidate these underlying mechanisms we established a model
system in vitro. Four antineoplastic drugs with different cellular
targets, which are commonly used in melanoma treatment, were
chosen to select stable drug-resistant sublines from the human
melanoma cell line MeWo. This panel of melanoma sublines
exhibiting low, various intermediate and high levels of resistance
to each drug was analysed subsequently with regard to its pharma-
cological characteristics, cross-resistance pattern (Kern et al,
1997) and activity of DNA repair mechanisms (Lage et al, 1999).
One of the mechanisms which have been identified to contribute
to resistance to antineoplastic drugs is mediated by a decreased
activity of DNA topoisomerase II (Topo II) (Danks et al, 1988).
This enzyme binds to double-stranded DNA, cleaves both strands,
passes in an ATP-dependent manner a second strand of DNA
through the cleaved site and rejoins the strands at the original site
of cleavage (Osheroff et al, 1994). During breakage-reunion reac-
tion, Topo II form a cleavable complex with DNA with the co-
valent linking of each Topo II subunit to each 5¢-phosphoryl end of
the cleaved DNA through a phosphotyrosyl bond (Liu et al, 1983).
Topo II inhibitors such as etoposide interfere with the breakage-
reunion reaction of Topo II by stabilizing this cleavable complex
that is supposed to play the decisive role in the cytotoxic effect of
Topo II-inhibiting agents (Nelson et al, 1984). The stabilized
cleavable complex leads to both single- and double-strand DNA
breaks, which can trigger pathways leading to cell death (Walker
et al, 1991). Accordingly, resistance to Topo II-interacting agents
can result from any process that leads to an altered binding of Topo
II to drugs or DNA and a reduced formation of cleavable
complexes.
In mammalian cells two Topo II isoforms, the 170 kDa Topo IIa
and the 180 kDa Topo IIb exist as homodimers. Their amino acid
sequences show homology at regions believed to be functionally
significant (72% identical amino acid residues; Jenkins et al,
1992), suggesting a comparable mode of action. In this study, we
analysed Topo IIa and IIb expression on mRNA and protein level
as well as Topo II activity in the subset of drug-resistant MeWo
variants. The results demonstrate that decreasing Topo II activity
closely correlates with increasing level of etoposide resistance, in
contrast to measurement of Topo II expression on protein or
mRNA level. Functional assays of Topo II activity may therefore
be essential for a reliable prediction of the drug sensitivity.
MATERIALS AND METHODS
Cell lines
The human melanoma cell line MeWo (Fogh et al, 1978) and drug-
resistant MeWo variants were selected in vitro and characterized
as described previously (Kern et al, 1997; Lage et al, 1999). The
selection conditions and the corresponding designation of the
strains were as follows: MeWo untreated (MeWo); MeWo-
cisplatin (MeWo CIS), 0.01 and 1.0 mg ml–1; MeWo-vindesine
(MeWo VIN), 0.5 and 5.0 ng ml–1; MeWo-etoposide (MeWo
ETO), 0.01, 0.1, 0.5 and 1.0 mg ml–1; and MeWo-fotemustine
(MeWo FOTE), 4 and 40 mg ml–1.
Northern blot
Northern blot analysis and polymerase chain reaction (PCR)-
based generation of cDNA hybridization probes encoding human
Topo IIa and IIb were performed as described previously (Lage
et al, 1999). Oligonucleotide primers used for PCR were
designed after alignment with published sequences encoding
Topo IIa (GenBank accession number J04088) and Topo IIb
(GenBank accession number X68060). Primers used for the
amplification of Topo IIa-specific sequences were topoIIa-fw,
5¢-CACAACTGGCCCTCTCTTCTGCGAC-3¢ and topoIIa-rev,
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5¢-GGGCAACCTTTACTTCTCGCTT-3¢, yielding an expected
amplificate of 562 bp; and those used for amplification of Topo
IIb-specific sequences were topoIIb-fw, 5¢-ACCTGGCCAGCG-
GAAAGTTTTATT-3¢ and topoIIb-rev, 5¢-CCTGTTCTTTATAT-
ACCTGTGTCC-3¢, yielding an expected amplificate of 647 bp.
Western blot
Western blot analysis of nuclear protein extracts was performed as
described previously (Lage et al, 1999). Topo II-specific anti-
bodies used were mouse monoclonal antibody Ki-S1 directed
against Topo IIa (Boege et al, 1995) (kindly provided by Dr U
Kellner, Kiel, Germany) and polyclonal rabbit antibodies directed
against Topo IIb (Boege et al, 1995) (Biotrend, Cologne,
Germany).
Topo II activity assay
Topo II catalytic activity in nuclear extracts of melanoma cells was
determined using the decatenation assay (Marini et al, 1980). The
standard reaction of the ATP-dependent decatenation of form I
kinetoplast DNA (kDNA) from C. fasciculata was carried out as
described previously (Kellner et al, 1997). Samples were analysed
by agarose gel electrophoresis and quantified densitometrically
after ethidium bromide staining.
RESULTS
Topo IIa mRNA and protein levels
The nuclear amount of Topo IIa protein was substantially
decreased in the three etoposide-selected cell variants (MeWo
ETO 0.1, MeWo ETO 0.5, MeWo ETO 1) exhibiting the highest
level of drug resistance in comparison to parental MeWo cells
(Figure 1A). The nuclear Topo IIa protein content was not altered
in MeWo ETO 0.01 and all other lines. Levels of Topo IIa mRNA
expression were analysed by Northern blot (Figure 1B). In the
high level drug-resistant melanoma sublines MeWo CIS 1, MeWo
ETO 1 and MeWo FOTE 40 and in MeWo ETO 0.1 a reduced
Topo IIa gene expression was found.
Topo IIb mRNA and protein levels
No Topo IIb protein-specific signal could be detected in the low
level etoposide-resistant cell line MeWo ETO 0.01 and in MeWo
ETO 0.5 (Figure 1A) indicating a considerable reduction of
nuclear Topo IIb content in these cells. Topo IIb mRNA levels
were decreased in three etoposide-resistant cell lines in parallel to
the increasing level of drug-resistance exhibited (Figure 1B). Low
level etoposide-resistant MeWo ETO 0.01 cells showed no signifi-
cant Topo IIb mRNA expression reduction when compared to
parental cells, whereas only a weak Topo IIb-specific signal could
be detected in the high level etoposide-resistant cell line MeWo
ETO 1. In addition, a decrease of Topo IIb mRNA level was
observed in the high level drug-resistant melanoma variants
MeWo CIS 1 and MeWo FOTE 40 and the low level vindesine-
resistant cell line MeWo VIN 0.5 compared to MeWo.
Topo II catalytic activity
Topo II catalytic activity was assayed by decatenation of kDNA
networks from C. fasciculata (Marini et al, 1980) using crude
nuclear extracts. The degree of decatenation of kDNA by Topo II
is proportional to the length of incubation. As shown in Figure 2A,
Topo II activities were decreased in etoposide-resistant melanoma
cells dependent on the level of etoposide resistance, as could be
seen by comparing band intensities of catenated and decatenated
kDNA with those of parental MeWo cells. The low level etopo-
side-resistant variant MeWo ETO 0.01 exhibited a Topo II decate-
nation activity which was similar to the activity of the parental
MeWo cells, while Topo II activity was approximately fourfold
lower using nuclear proteins obtained from intermediate level
etoposide-resistant subline MeWo ETO 0.1. In extracts prepared
from MeWo sublines exhibiting the highest level of etoposide
resistance, i.e. MeWo ETO 0.5 and MeWo ETO 1, an approxi-
mately tenfold reduction of Topo II decatenation activity could be
observed. Topo II catalytic activities of nuclear extracts prepared
from the remaining drug-resistant melanoma cells were equivalent
to parental MeWo cells (Figure 2B).
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Figure 1 Western blot analysis (A) of proteins prepared from crude nuclear
extracts from the human melanoma cell line MeWo and the panel of drug-
resistant variants harvested in the log-phase of growth. Nuclear proteins 
(40 mg each) were size fractionated by gel electrophoresis, transferred to a
membrane, incubated with antibodies against Topo IIa and IIb and visualized
by chemiluminescence. Sizes of Topo IIa- and IIb-specific signals were
verified by comparison to molecular weight markers. Northern blot analysis
(B) of genes encoding Topo IIa and IIb in the human melanoma cell line
MeWo and various derived drug-resistant variants. Total cellular RNA (10 mg
per lane) was size fractionated on a 1% agarose gel, transferred to a nylon
membrane and hybridized with 32P-labelled cDNA probes encoding Topo IIa
or Topo IIb. As control, the blots were probed with a cDNA probe encoding
phosphoglycerate kinase (PGK)DISCUSSION
Melanoma is well known for its high intrinsic resistance to anti-
neoplastic drugs used for therapy. Although various in vitro
models have been established to study drug resistance of different
malignancies, the mechanisms conferring resistance to melanoma
cells are currently unclear. In this study we used various drug-
resistant melanoma variants selected for anticancer drugs
commonly applied in melanoma treatment. Melanoma cells
selected for resistance against etoposide showed the broadest
range of cross-resistance (Kern et al, 1997) including resistance to
other Topo II inhibitors like teniposide and amsacrine (data not
shown). By definition such phenotype in the absence of P-glyco-
protein (data not shown), the hallmark for classical multidrug
resistance (MDR), is designated as atypical MDR (Danks et al,
1988). Since Topo II represents the target molecule of etoposide,
alterations of the enzyme may affect biological activity and there-
fore be mediating etoposide- as well as cross-resistance.
Using alternative drug-resistant in vitro systems derived from
various tissues it was demonstrated that altered Topo II expression
and activity led to drug resistance against Topo II inhibitors and to
cross-resistance to anthracyclines and mitoxantrone. The alter-
ation of Topo II activity can be caused by various mechanisms
including reduction of the cellular amount (Liu, 1989), modulation
of the catalytic activity via phosphorylation (Takano et al, 1991),
or by mutations in Topo II encoding genes (Danks et al, 1993).
However, it could be demonstrated that Topo II isolated from
etoposide-resistant melanoma cells was much less susceptible to
the drug-induced cleavable complex formation when compared to
the non-resistant parental cell line (Campain et al, 1993). This
phenomenon was found to be caused by a mutation in the Topo
IIa-encoding gene resulting to a deletion of alanine 429. Sublines
of increasing resistance were tested, and the prevalence of the
mutant Topo IIa encoding mRNA increased in these cells over
wild-type in parallel with their resistance to etoposide (Campain et
al, 1994).
Alteration of Topo II expression has not yet reported in any
drug-resistant melanoma cell line. Using a panel of drug-resistant
MeWo sublines it could be demonstrated that a reduction of
nuclear content of both Topo II isoforms and catalytic Topo II
activity corresponded to an increasing level of drug resistance. The
reduction of Topo II activity was accompanied by a decrease of the
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Figure 2 Topo II activity determined in crude nuclear extracts prepared from parental melanoma cells MeWo and derived sublines selected for etoposide (A)
and sublines resistant against cisplatin, vindesine and fotemustine (B). Topo II activity was measured by decatenation of kDNA networks from C. fasciculata as
described in Materials and Methods. Reaction mixtures containing 0.4 mg nuclear proteins and 0.15 mg kDNA were incubated for various times as indicated at
37°C. The degree of decatenation of kDNA by Topo II is proportional to the length of incubation. As controls linear kDNA, digested with XhoI and complete
decatenated kDNA, digested with Topo II were loaded on the gels. Near the top of the gels catenated kDNA is visible, while decatenated kDNA appears as
nicked, open circular DNA (medium band) and relaxed DNA (band at the bottom of the gels)
B
MeWo
CIS 1
MeWo
CIS 0.01
MeWo
VIN 0.5
MeWo
VIN 5
MeWo
FOTE 4
L
i
n
e
a
r
 
k
D
N
A
D
e
c
a
t
e
n
a
t
e
d
 
k
D
N
A
0
 
m
i
n
0
.
5
 
m
i
n
1
 
m
i
n
2
 
m
i
n
5
 
m
i
n
7
 
m
i
n
1
0
 
m
i
n
1
5
 
m
i
n
2
0
 
m
i
n
MeWo
FOTE 40Topoisomerase II in melanoma 491
British Journal of Cancer (2000) 82(2), 488–491 © 2000 Cancer Research Campaign
nuclear content of both Topo II isoenzymes. However, the
detectable amount of nuclear Topo II proteins was not equally
distributed between both Topo II isoforms. Increasing resistance
level (MeWo ETO 0.1, MeWo ETO 0.5 and MeWo 1) led to a
reduction of the nuclear protein content of both Topo II isoen-
zymes. In MeWo ETO 0.01 exhibiting the lowest level of etopo-
side resistance no Topo IIb protein was detectable in contrast to
unaltered Topo IIa nuclear levels. Since Topo IIa mRNA expres-
sion levels were not or only slightly altered in the etoposide-
selected melanoma lines, other post-transcriptional or
post-translational mechanisms might be involved in regulating
Topo IIa activity, i.e. decreased protein biosynthesis or decreased
transport of Topo IIa into the nucleus. Similar data were reported
from a gastric carcinoma cell line showing a decreased Topo II
activity (Son et al, 1998). In this cell line a reduced cellular content
of Topo IIa was measured by an immunoblotting technique, but
Northern blotting analysis revealed no decreased expression level
of Topo IIa-encoding mRNA. Our observations have implications
and clinical relevance since the data suggest that decrease of Topo
II activity contributes to the development of acquired drug resis-
tance in melanoma cells.
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